RU96120088A - ANTITROMBOTIC AGENTS - Google Patents
ANTITROMBOTIC AGENTSInfo
- Publication number
- RU96120088A RU96120088A RU96120088/04A RU96120088A RU96120088A RU 96120088 A RU96120088 A RU 96120088A RU 96120088/04 A RU96120088/04 A RU 96120088/04A RU 96120088 A RU96120088 A RU 96120088A RU 96120088 A RU96120088 A RU 96120088A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- methyl
- aminoiminomethyl
- hydrogen
- prolinamide
- Prior art date
Links
- -1 homoprolinyl Chemical group 0.000 claims 45
- 150000001875 compounds Chemical class 0.000 claims 34
- 229910052739 hydrogen Inorganic materials 0.000 claims 33
- 239000001257 hydrogen Substances 0.000 claims 32
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 31
- 125000000217 alkyl group Chemical group 0.000 claims 29
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 23
- 239000011780 sodium chloride Substances 0.000 claims 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 22
- 239000012453 solvate Substances 0.000 claims 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 16
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 8
- 125000005842 heteroatoms Chemical group 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 239000001301 oxygen Substances 0.000 claims 8
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 8
- 239000011593 sulfur Substances 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 5
- 125000004429 atoms Chemical group 0.000 claims 4
- 125000002619 bicyclic group Chemical group 0.000 claims 4
- 125000004432 carbon atoms Chemical group C* 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 4
- 125000001624 naphthyl group Chemical group 0.000 claims 4
- 125000006239 protecting group Chemical group 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 3
- 230000000875 corresponding Effects 0.000 claims 3
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims 3
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 3
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 3
- NKCXQMYPWXSLIZ-PSRDDEIFSA-N (2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-m Chemical compound O=C([C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C(C)C)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NKCXQMYPWXSLIZ-PSRDDEIFSA-N 0.000 claims 2
- PXXJHWLDUBFPOL-UHFFFAOYSA-N Benzamidine Chemical group NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 108090000190 Thrombin Proteins 0.000 claims 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims 2
- 229960004072 thrombin Drugs 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical group OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 238000005755 formation reaction Methods 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 238000005984 hydrogenation reaction Methods 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000005004 perfluoroethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001681 protective Effects 0.000 claims 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 0 C[C@@]1(CNC2N(CC(CC3)CCC3C=N)C2)N(*)CCC1 Chemical compound C[C@@]1(CNC2N(CC(CC3)CCC3C=N)C2)N(*)CCC1 0.000 description 1
Claims (1)
X-Y-NH-(CH2)r-G
где X обозначает пролинил; гомопролинил;
Rm-(CH2)g-NH-CH2-C(O)-,
где Rd обозначает карбокси или метилсульфонил;
Re обозначает NHRc, NHCORc или NHCOORc, где Rc обозначает C1-C10 алкил, C3-C8 циклоалкил или C3-C8 циклоалкил C1-C6 алкил с 4-10 атомами углерода;
T обозначает C3-C8 циклоалкил, C1-C8 алкил,
a = 0,1 или 2; и
Q обозначает -OH, C1-C4 алкокси или -NH-A;
A обозначает водород; C1-C4 алкил, R"SO2-, R"OC(O)-, R"C(O)-, RnC(O)-, или -(CH2)g -Rm;
g обозначает 1, 2 или 3;
B обозначает водород или C1-C4 алкил;
R' обозначает водород или C1-C4 алкил;
R" обозначает или C1-C4 алкил, C1-C4 перфторалкил, -(CH2)d -Rm, или незамещенный или замещенный арил, где арил обозначает фенил, нафтил, 5- или 6-членное незамещенное или замещенное ароматическое гетероциклическое кольцо, содержащее один или два гетероатома, которые являются одинаковыми или разными и которые выбраны из серы, кислорода и азота, или 9- или 10-членную, незамещенную или замещенную конденсированную бициклическую ароматическую гетероциклическую группу с одним или двумя гетероатомами, которые являются одинаковыми или разными и которые выбраны из серы, кислорода или азота;
Rm обозначает -COORв, - SO2(C1-C4)-алкил, -SO3H, -P(O) (ORв)2 или тетразол-5-ил;
Rn обозначает -COORв или тетразол-5-ил; каждый Rв, независимо, обозначает водород или C1-C4 алкил;
d = 1, 2 или 3;
m = 0, 1 или 2;
n = 0, 1 или 2; и
Z обозначает водород, C1-C4 алкил, C1-C4 алкокси, гидрокси, галоген или RaSO2NH-, где Ra обозначает C1-C4 алкил;
Y обозначает:
где Rg обозначает C1-C6 алкил, C3-C8 циклоалкил или -(CH2)p-L-(CH2)q -T';
Rp обозначает водород, C1-C4 алкил, C3-C8 циклоалкил -(CH2)p-L-(CH2)q -T';
где p = 0, 1, 2, 3 или 4;
L обозначает связь, -О-, -S- или -NH-;
q обозначает 0, 1, 2 или 3; и
T' обозначает водород, C1-C4 алкил, C3-C8 циклоалкил, -COOH, -CONH2 или Ar, где Ar обозначает незамещенный или замещенный арил, где арилом является фенил, нафтил, 5- или 6-членное незамещенное или замещенное ароматическое гетероциклическое кольцо с одним или двумя гетероатомами, которые являются одинаковыми или разными и которые выбраны из серы, кислорода и азота, или 9- или 10-членную, незамещенную или замещенную конденсированную бициклическую ароматическую гетероциклическую группу с одним или двумя гетероатомами, которые являются одинаковыми или разными и которые выбраны из серы, кислорода и азота;
RY обозначает -CH2-, -O-, -S- или -NH-;
RZ обозначает связь или, вместе с RY и тремя соседними атомами углерода, образуют насыщенное карбоциклическое кольцо с 5-8 атомами, одним атомом из которых может быть -O-, -S- или -NH-;
r = 1, 2 или 3;
G обозначает -(CH2)s -R, где s равно 0-5;
-CH=CH-(CH2)t -R, где t обозначает 0-3; или G обозначает:
где D и E, каждый, независимо, обозначает N или CH;
k = 0 или 1;
b = 0 или 1;
M обозначает S, O или NH;
каждый W, независимо обозначает N или CH; и
где от одного до всех иных незамещенных атомов углерода ароматического или гетероциклического кольца:
могут содержать фтор в качестве заместителя; или его фармацевтически приемлемая соль; или фармацевтически приемлемый сольват указанного соединения или его соль; при условии, что A не обозначает водород или трет-бутилоксикарбонил, когда G обозначает -(CH2)s -NH-C(NH)NH2; Y обозначает незамещенный пролинил (Rp обозначает водород) и T обозначает:
и, кроме того, при условии, что R не является амино или гуанидино, когда r = 1 и S = 0; и при условии, кроме того, что A не является водородом, C1-C4 алкилом, метилсульфонилом или (CH2)g -Rm, когда G обозначает (CH2)s -R, где R обозначает:
Y обозначает:
незамещенный пролинил (Rp обозначает водород) или 4-гидроксипролинил (Rp обозначает OH); R' обозначает водород; T обозначает цмклогексил и Q обозначает: -NH-A; и, кроме того, при условии, что R"SO2 не является арилсульфонилом, когда G обозначает (CH2)s -R, где R обозначает:
Y обозначает незамещенный пролинил (Rp обозначает водород) или 4-гидроксипролинил (Rp обозначает SCH3) и Q обозначает -NH-A-; и, кроме того, при условии, что A не является R"SO2-, когда G обозначает:
T обозначает C1-C8 алкил,
и Q обозначает -NH-A.1. The compound corresponding to formula I:
XY-NH- (CH 2 ) r -G
where X is proinyl; homoprolinyl;
R m - (CH 2 ) g —NH — CH 2 —C (O) -,
where R d is carboxy or methylsulfonyl;
R e is NHR c , NHCOR c or NHCOOR c , where R c is C 1 -C 10 alkyl, C 3 -C 8 cycloalkyl or C 3 -C 8 cycloalkyl C 1 -C 6 alkyl with 4-10 carbon atoms;
T is C 3 -C 8 cycloalkyl, C 1 -C 8 alkyl,
a = 0.1 or 2; and
Q is —OH, C 1 -C 4 alkoxy or —NH — A;
A is hydrogen; C 1 -C 4 alkyl, R "SO 2 -, R" OC (O) -, R "C (O) -, R n C (O) -, or - (CH 2 ) g -R m ;
g is 1, 2 or 3;
B is hydrogen or C 1 -C 4 alkyl;
R 'is hydrogen or C 1 -C 4 alkyl;
R "is either C 1 -C 4 alkyl, C 1 -C 4 perfluoroalkyl, - (CH 2 ) d -R m , or unsubstituted or substituted aryl, where aryl is phenyl, naphthyl, 5- or 6-membered unsubstituted or substituted an aromatic heterocyclic ring containing one or two heteroatoms that are the same or different and which are selected from sulfur, oxygen and nitrogen, or a 9- or 10-membered, unsubstituted or substituted fused bicyclic aromatic heterocyclic group with one or two heteroatoms that are the same or different and which selected from sulfur, oxygen or nitrogen;
R m represents -COOR a, - SO 2 (C 1 -C 4) -alkyl, -SO 3 H, -P (O) (OR b) 2 or tetrazol-5-yl;
R n denotes a -COOR group or a tetrazol-5-yl; each R a independently is hydrogen or C 1 -C 4 alkyl;
d is 1, 2 or 3;
m is 0, 1 or 2;
n is 0, 1 or 2; and
Z is hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, hydroxy, halogen or R a SO 2 NH-, where R a is C 1 -C 4 alkyl;
Y is:
where R g is C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl or - (CH 2 ) p -L- (CH 2 ) q -T ';
R p is hydrogen, C 1 -C 4 alkyl, C 3 -C 8 cycloalkyl - (CH 2 ) p -L- (CH 2 ) q -T ';
where p = 0, 1, 2, 3 or 4;
L is a bond, —O—, —S— or —NH—;
q is 0, 1, 2 or 3; and
T 'is hydrogen, C 1 -C 4 alkyl, C 3 -C 8 cycloalkyl, -COOH, -CONH 2 or Ar, where Ar is unsubstituted or substituted aryl, where aryl is phenyl, naphthyl, 5- or 6-membered unsubstituted or a substituted aromatic heterocyclic ring with one or two heteroatoms that are the same or different and which are selected from sulfur, oxygen and nitrogen, or a 9- or 10-membered, unsubstituted or substituted condensed bicyclic aromatic heterocyclic group with one or two heteroatoms that are identical or pa GOVERNMENTAL and which are selected from sulfur, oxygen and nitrogen;
R Y is —CH 2 -, —O—, —S— or —NH—;
R Z is a bond or, together with R Y and three adjacent carbon atoms, form a saturated carbocyclic ring with 5-8 atoms, one atom of which may be —O—, —S— or —NH—;
r is 1, 2 or 3;
G is - (CH 2 ) s —R, where s is 0-5;
-CH = CH- (CH 2 ) t -R, where t is 0-3; or G is:
where D and E are each independently N or CH;
k is 0 or 1;
b is 0 or 1;
M is S, O or NH;
each W independently represents N or CH; and
where from one to all other unsubstituted carbon atoms of an aromatic or heterocyclic ring:
may contain fluorine as a substituent; or a pharmaceutically acceptable salt thereof; or a pharmaceutically acceptable solvate of the compound or a salt thereof; with the proviso that A is not hydrogen or tert-butyloxycarbonyl when G is - (CH 2 ) s —NH — C (NH) NH 2 ; Y is unsubstituted proinyl (R p is hydrogen) and T is:
and, furthermore, provided that R is not amino or guanidino when r = 1 and S = 0; and provided, in addition, that A is not hydrogen, C 1 -C 4 alkyl, methylsulfonyl or (CH 2 ) g -R m when G is (CH 2 ) s -R, where R is:
Y is:
unsubstituted proinyl (R p is hydrogen) or 4-hydroxyprolynyl (R p is OH); R 'is hydrogen; T is cyclohexyl and Q is: —NH — A; and further provided that R условии SO 2 is not arylsulfonyl when G is (CH 2 ) s —R, where R is:
Y is unsubstituted proinyl (R p is hydrogen) or 4-hydroxyprolynyl (R p is SCH 3 ) and Q is —NH — A—; and, in addition, provided that A is not R "SO 2 - when G denotes:
T is C 1 -C 8 alkyl,
and Q is —NH — A.
T обозначает C3-C8 циклоалкил, C1-C8 алкил,
a=0 или 1;
Q обозначает -OH, C1-C4 алкокси или -NH-A;
A обозначает водород, C1-C4 алкил, R"SO2-, R"OC(O)-, R"C(O)- или -(CH2)g - COOH;
g = 1, 2 или 3;
В обозначает водород или C1-C4 алкил;
R-' обозначает водород или C1-C4 алкил;
R" обозначает C1-C4 алкил, C1-C4 перфторалкил, -(CH2)d -COOH, или незамещенный или замещенный арил, где арил обозначает фенил, нафтил, 5- или 6-членное незамещенное или замещенное ароматическое гетероциклическое кольцо с одним или двумя гетероатомами, которые являются одинаковыми или разными и которые выбраны из серы, кислорода и азота, или 9- или 10-членную, незамещенную или замещенную конденсированную бициклическую ароматическую гетероциклическую группу с одним или двумя гетероатомами, которые являются одинаковыми или разными и которые выбраны из серы, кислорода и азота;
d = 1, 2 или 3; m = 0, 1 или 2; n = 0, 1 или 2; и
Z обозначает водород, C1-C4 алкил, C1-C4 алкокси, гидроксил, галоген или RaSO2NH-, где Ra обозначает C1-C4 алкил;
Y обозначает:
где Rg обозначает C1-C6 алкил, C3-C8 циклоалкил или -(CH2)p-L-(CH2)q -T';
Rp обозначает водород, C1-C6 алкил, C3-C8 циклоалкил или -(CH2)p-L-(CH2)q -T';
где p = 0, 1, 2, 3 или 4; L обозначает связь, -O-, -S- или -NH-;
q = 0, 1, 2 или 3; T' обозначает водород, C1-C4 алкил, C3-C8 циклоалкил, -COOH, -CONH2 или Ar, где Ar обозначает незамещенный или замещенный арил, где арил обозначает фенил, нафтил, 5- или 6-членное, незамещенное или замещенное, ароматическое гетероциклическое кольцо с одним или двумя гетероатомами, которые являются одинаковыми или разными и которые выбраны из серы, кислорода и азота или 9- или 10-членную, незамещенную или замещенную, конденсированную бициклическую ароматическую гетероциклическую группу с одним или двумя гетероатомами, которые являются одинаковыми или разными и которые выбраны из серы, кислорода и азота;
RY обозначает -CH2-, -O-, -S- или -NH-; и
RZ обозначает связь или, вместе с RY и тремя соседними атомами углерода, образует насыщенное карбоциклическое кольцо с 5-8 атомами, один атом из которых может представлять собой -O-, -S- или -NH-;
r равно 1 или 2; и
G обозначает -(CH2)S -R, где S = 0-5, -CH=CH-CH2)t -R, где t = 0-3;
где D и E, каждый, независимо, обозначают N или CH;
к = 0 или 1;
в = 0 или 1;
М обозначает S, O или H;
каждый из W, независимо, обозначает N или CH;
R обозначает:
или его фармацевтически приемлемая соль; или фармацевтически приемлемый сольват вышеуказанного соединения или его соль; при условии, что A не обозначает водород или трет-бутилоксикарбонил, когда G обозначает -(CH2)S -NH-C(NH)NH2; Y обозначает незамещенный пролинил (Rp обозначает водород) и T обозначает:
и при условии, кроме того, что R не обозначает амино или гуанидино, когда r = 1 и S = 0; и при условии, кроме того, что А не обозначает водород, C1-C4 алкил, метилсульфонил или -(CH2)g -COOH, когда G обозначает: -(CH2)S -R, где R обозначает:
Y обозначает:
незамещенный пролинил (Rp обозначает Н) или 4-гидроксипролинил (Rp обозначает ОН); R' обозначает водород; Т обозначает циклогексил и Q обозначает: -NH-A; и при условии, кроме того, что R"SO2 не обозначает арилсульфонил, когда G обозначает -(CH2)S -R, где R обозначает:
Y обозначает незамещенный пролинил (Rp обозначает водород) или 4-метил-тиопролинил (Rp обозначает -SCH3); и Q = -NH-A; и при условии, кроме того, что А не обозначает R"SO2-, когда G обозначает
Т обозначает C1-C8 алкил,
и Q = - NH-A.2. The compound of formula I or its salt or solvate according to claim 1, where X is proinyl, homoprolinyl,
T is C 3 -C 8 cycloalkyl, C 1 -C 8 alkyl,
a is 0 or 1;
Q is —OH, C 1 -C 4 alkoxy or —NH — A;
A is hydrogen, C 1 -C 4 alkyl, R "SO 2 -, R" OC (O) -, R "C (O) - or - (CH 2 ) g - COOH;
g is 1, 2 or 3;
B is hydrogen or C 1 -C 4 alkyl;
R - ' is hydrogen or C 1 -C 4 alkyl;
R "is C 1 -C 4 alkyl, C 1 -C 4 perfluoroalkyl, - (CH 2 ) d -COOH, or unsubstituted or substituted aryl, where aryl is phenyl, naphthyl, 5- or 6-membered unsubstituted or substituted aromatic heterocyclic a ring with one or two heteroatoms that are the same or different and which are selected from sulfur, oxygen and nitrogen, or a 9- or 10-membered, unsubstituted or substituted fused bicyclic aromatic heterocyclic group with one or two heteroatoms that are the same or different and which are selected of sulfur, oxygen and nitrogen;
d is 1, 2 or 3; m is 0, 1 or 2; n is 0, 1 or 2; and
Z is hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, hydroxyl, halogen or R a SO 2 NH-, where R a is C 1 -C 4 alkyl;
Y is:
where R g is C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl or - (CH 2 ) p -L- (CH 2 ) q -T ';
R p is hydrogen, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl or - (CH 2 ) p -L- (CH 2 ) q -T ';
where p = 0, 1, 2, 3 or 4; L is a bond, —O—, —S— or —NH—;
q is 0, 1, 2 or 3; T 'is hydrogen, C 1 -C 4 alkyl, C 3 -C 8 cycloalkyl, -COOH, -CONH 2 or Ar, where Ar is unsubstituted or substituted aryl, where aryl is phenyl, naphthyl, 5- or 6-membered, unsubstituted or substituted, aromatic heterocyclic ring with one or two heteroatoms that are the same or different and which are selected from sulfur, oxygen and nitrogen, or a 9- or 10-membered, unsubstituted or substituted, fused bicyclic aromatic heterocyclic group with one or two heteroatoms, which are the same or p znymi and which are selected from sulfur, oxygen and nitrogen;
R Y is —CH 2 -, —O—, —S— or —NH—; and
R Z represents a bond or, together with R Y and three adjacent carbon atoms, forms a saturated carbocyclic ring with 5-8 atoms, one atom of which may be —O—, —S— or —NH—;
r is 1 or 2; and
G is - (CH 2 ) S —R, where S = 0-5, —CH = CH — CH 2 ) t —R, where t = 0-3;
where D and E are each independently N or CH;
k = 0 or 1;
c = 0 or 1;
M is S, O or H;
each W, independently, is N or CH;
R is:
or a pharmaceutically acceptable salt thereof; or a pharmaceutically acceptable solvate of the above compound or a salt thereof; with the proviso that A is not hydrogen or tert-butyloxycarbonyl when G is - (CH 2 ) S —NH — C (NH) NH 2 ; Y is unsubstituted proinyl (R p is hydrogen) and T is:
and provided, in addition, that R is not amino or guanidino when r = 1 and S = 0; and provided, in addition, that A is not hydrogen, C 1 -C 4 alkyl, methylsulfonyl or - (CH 2 ) g -COOH when G is: - (CH 2 ) S -R, where R is:
Y is:
unsubstituted proinyl (R p is H) or 4-hydroxyprolynyl (R p is OH); R 'is hydrogen; T is cyclohexyl and Q is: —NH — A; and provided, in addition, that R ″ SO 2 does not mean arylsulfonyl when G is - (CH 2 ) S —R, where R is:
Y is unsubstituted proinyl (R p is hydrogen) or 4-methylthioprolinyl (R p is —SCH 3 ); and Q = —NH — A; and provided, in addition, that A does not mean R "SO 2 - when G is
T represents C 1 -C 8 alkyl,
and Q = - NH-A.
-S(O)hNH2, -S(O)hNH(C1-C4-алкил)- или -S(O)hN-(C1-C4-алкил)2, где h = 0, 1 или 2; и "j" = 0, 1, 2, 3 или 4.3. The compound or its salt or solvate according to claim 1 or 2, wherein the alkyl, alone or as part of another substituent, is methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl or sec- butyl; perfluoroalkyl by itself or as part of another substituent means trifluoromethyl, perfluoroethyl, perfluoro-n-propyl, perfluoroisopropyl, perfluoro-n-butyl, perfluoro-tert-butyl, perfluoroisobutyl, or perfluoro-sec-butyl; C 3 -C 8 cycloalkyl is cyclopropyl, methylcyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-methylcyclohexyl or cyclooctyl; halogen means chlorine, fluorine, bromine or iodine; A 5- or 6-membered heterocyclic ring means furyl, thienyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyranyl, pyridinyl, pyrimidinyl, pyrazinyl, oxazinyl or thiazinyl; A 9- or 10-membered heterocyclic ring is indolyl, benzothienyl, benzofuryl, benzoxazolyl, benzoisoxazolyl, benzopyrazolyl, quinolinyl, isoquinolinyl, benzimidazolyl or benzothiazolyl; and, in addition, where any of the aromatic or heterocyclic groups listed for the definition of Ar or R ″ is independently unsubstituted or substituted with one or two substituents that can give a stable structure, independently selected from the group consisting of from halogen, hydroxyl, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, amino (-NH 2 ), mono (C 1 -C 4 -alkyl) amino, - (CH 2 ) j COOH, mercapto, - S- (O) h - (C 1 -C 4 -alkyl) -group, -NHS (O) h (C 1 -C 4 -alkyl), -NHC (O) (C 1 -C 4 -alkyl),
-S (O) h NH 2 , -S (O) h NH (C 1 -C 4 -alkyl) - or -S (O) h N- (C 1 -C 4 -alkyl) 2 , where h = 0 , 1 or 2; and "j" = 0, 1, 2, 3, or 4.
гомопролинил, 1- или 3-Tiq, или 1- или 3-Riq; Y обозначает пролинил; и Q обозначает: NHA, где А обозначает водород или R"SO2-; R' обозначает водород; Z обозначает водород и В обозначает водород; и R обозначает гуанидино или амидино.4. The compound or its salt or solvate according to claims 1, 2 or 3, characterized in that X is:
homoprolinyl, 1- or 3-Tiq, or 1- or 3-Riq; Y is proinyl; and Q is: NHA, where A is hydrogen or R "SO 2 -; R 'is hydrogen; Z is hydrogen and B is hydrogen; and R is guanidino or amidino.
где Т обозначает циклогексил, а = 1; R' обозначает водород и Q обозначает: -NH-A, где А обозначает водород, R"SO2- или -(CH2)g -COOH.6. The compound or its salt or solvate according to claims 1, 2 or 3, characterized in that X represents:
where T is cyclohexyl, a = 1; R 'is hydrogen and Q is: -NH-A, where A is hydrogen, R "SO 2 - or - (CH 2 ) g -COOH.
где бензамидиновое кольцо незамещено или может содержать один или два фтор заместителей: б) соединения формулы Ib:
и в) соединения формулы Ic:
где D = N или CH; и Х принимает любое из значений по пп.1-4 и 6-8.10. The compound or its pharmaceutically acceptable salt or solvate, characterized in that the compound is selected from: a) a compound of formula Ia:
where the benzamidine ring is unsubstituted or may contain one or two fluorine substituents: b) compounds of formula Ib:
and c) compounds of formula Ic:
where D = N or CH; and X takes any of the values according to claims 1-4 and 6-8.
где R' обозначает водород; а равно 1; Т обозначает циклогексил или фенил, и Q обозначает -NH-A, где А обозначает водород, этилсульфонил или карбоксиметил.12. The compound or its salt or solvate according to claim 10 or 11, characterized in that X represents
where R 'is hydrogen; a is 1; T is cyclohexyl or phenyl, and Q is —NH — A, where A is hydrogen, ethylsulfonyl or carboxymethyl.
а) D-фенилаланил-N-[[4-(аминоиминометил)фенил]метил]-L-пролинамид;
б) N-[[4-(аминоиминометил)фенил] метил]-1-[[(4aS, 8aS)-декагидро-1(R)-изохинолинил]карбонил]-L-пролинамид;
в) N-(этилсульфонил)-D-фенилаланил-N-[[4-(аминоиминометил)фенил] метил] -L-пролинамид;
г) (S-цис)-N-[[4-(аминоиминометил)фенил]метил]-1-[N-(этилсульфонил)-D-фенилглицил]-1Н-индол-2-карбоксамид;
д) (S-цис)-N-[[4-(аминоиминометил)фенил]метил]-1-[N-(этилсульфонил)-D-фенилаланил]-1H-индол-2-карбоксамид;
е) N-(карбоксиметил)-D-фенилаланил-N-[[4-(аминоиминометил)фенил] метил] -L-пролинамид;
ж) N-(карбоксиметил)-D-циклогексилаланил-N-[[4-(аминоиминометил)фенил] метил]-L-пролинамид;
з) (S-цис)-N-[[4-(аминоиминометил)фенил]метил]-1-[N-(карбоксиметил)-D-циклогексилаланил]-1H-индол-2-карбоксамид;
и) D-циклогексилаланил-N-[[4-(аминоиминометил)фенил]метил]-L-пролинамид;
к) N-(2-карбоксиэтил)-D-циклогексилаланил-N-[[4-аминоиминометил)фенил] метил]-L-пролинамид;
л) N-(карбоксиметил)-D-циклогексилаланил-N-[[1-(аминоиминометил)-гексагидропиридин-4-ил]метил]-L-пролинамид;
м) N-(карбоксиметил)-D-циклогексилаланил-N-[[5-(аминоиминометил)тиофен-2-ил]метил]-L-пролинамид;
н) N-(карбоксиметил)-D-циклогексилаланил-N-[[5-(аминоиминометил)пиридин-2-ил]метил]-L-пролинамид;
о) N-(карбоксиметил)-D-циклогексилаланил-N-[[5-(аминоиминометил)-1,2,3,4-тетрагидропиридин-2-ил]метил]-L-пролинамид;
п) N-(карбоксиметил)-D-циклогексилаланил-N-[[6-(аминоиминометил)-пиридазин-3-ил]метил]-L-пролинамид;
р) N-(карбоксиметил)-D-циклогексилаланил-N-[[1-(аминоиминометил)-1,2,3,4-тетрагидропиридин-4-ил]метил]-L-пролинамид;
с) N-(карбоксиметил)-D-циклогексилаланил-N-[[4-(аминоиминометил)-2-фторфенил]метил]-L-пролинамид;
т) N-(карбоксиметил)-D-циклогексилаланил-N-[[4-(аминоиминометил)-2,6-дифторфенил]метил]-L-пролинамид;
у) N-(этилсульфонил)-D-циклогексилаланил-N-[[4-(аминоиминометил)фенил] метил]-L-пролинамид;
ф) N-(карбоксиметил)-D-циклогексилглицил-N-[[4-(аминоиминометил)фенил] метил]-L-пролинамид;
х) N-(карбоксиметил)-D-гомофенилаланил-N-[[4-(аминоиминометил)фенил]метил]-L-пролинамид;
ц) N-(карбоксиметил)-D-гомоциклогексилаланил-N-[[4-(аминоиминометил)фенил]метил]-L-пролинамид;
ч) N-(метилсульфонилацетил)-L-циклогексилаланил-N-[[4-(аминоиминометил)фенил]метил]-L-пролинамид;
14. Соединение или его соль или сольват по п.1, отличающееся тем, что оно выбрано из следующих соединений:
I) (S-цис)-N-[[4-(аминоиминометил)фенил]метил]-1-[N-(этилсульфонил)-D-фенилаланил]-1H-индол-2-карбоксамид;
II) N-(карбоксиметил)-D-фенилаланил-N-[[4-(аминоиминометил)фенил]метил] -L-пролинамид;
III) N-(карбоксиметил)-D-циклогексилаланил-N-[[4-(аминоиминометил)фенил] метил]-L-пролинамид;
IV) D-циклогексилаланил-N-[[4-(аминоиминометил)фенил] метил]-L-пролинамид;
V)N-(карбоксиметил)-D-циклогексилаланил-N-[[5-(аминоиминометил)-тиофен-2-ил]метил]-L-пролинамид;
VI) N-(карбоксиметил)-D-циклогексилаланил-N-[[1-(аминоиминометил)-1, 2, 3, 4-тетрагидропиридин-4-ил]метил]-L-пролинамид;
VII)N-(карбоксиметил)-D-циклогексилаланил-N-[[4-(аминоиминометил)-2-фторфенил]метил]-L-пролинамид;
VIII) N-(карбоксиметил)-D-циклогексилаланил-N-[[4-(аминоиминометил)-2,6-дифторфенил]метил]-L-пролинамид.13. The compound or its salt or solvate according to claim 1, characterized in that it is selected from the following compounds:
a) D-phenylalanyl-N - [[4- (aminoiminomethyl) phenyl] methyl] -L-prolinamide;
b) N - [[4- (aminoiminomethyl) phenyl] methyl] -1 - [[(4aS, 8aS) -decahydro-1 (R) -isoquinolinyl] carbonyl] -L-prolinamide;
c) N- (ethylsulfonyl) -D-phenylalanyl-N - [[4- (aminoiminomethyl) phenyl] methyl] -L-prolinamide;
d) (S-cis) -N - [[4- (aminoiminomethyl) phenyl] methyl] -1- [N- (ethylsulfonyl) -D-phenylglycyl] -1H-indole-2-carboxamide;
d) (S-cis) -N - [[4- (aminoiminomethyl) phenyl] methyl] -1- [N- (ethylsulfonyl) -D-phenylalanyl] -1H-indole-2-carboxamide;
e) N- (carboxymethyl) -D-phenylalanyl-N - [[4- (aminoiminomethyl) phenyl] methyl] -L-prolinamide;
g) N- (carboxymethyl) -D-cyclohexylalanyl-N - [[4- (aminoiminomethyl) phenyl] methyl] -L-prolinamide;
h) (S-cis) -N - [[4- (aminoiminomethyl) phenyl] methyl] -1- [N- (carboxymethyl) -D-cyclohexylalanyl] -1H-indole-2-carboxamide;
i) D-cyclohexylalanyl-N - [[4- (aminoiminomethyl) phenyl] methyl] -L-prolinamide;
k) N- (2-carboxyethyl) -D-cyclohexylalanyl-N - [[4-aminoiminomethyl) phenyl] methyl] -L-prolinamide;
k) N- (carboxymethyl) -D-cyclohexylalanyl-N - [[1- (aminoiminomethyl) hexahydropyridin-4-yl] methyl] -L-prolinamide;
m) N- (carboxymethyl) -D-cyclohexylalanyl-N - [[5- (aminoiminomethyl) thiophen-2-yl] methyl] -L-prolinamide;
m) N- (carboxymethyl) -D-cyclohexylalanyl-N - [[5- (aminoiminomethyl) pyridin-2-yl] methyl] -L-prolinamide;
o) N- (carboxymethyl) -D-cyclohexylalanyl-N - [[5- (aminoiminomethyl) -1,2,3,4-tetrahydropyridin-2-yl] methyl] -L-prolinamide;
o) N- (carboxymethyl) -D-cyclohexylalanyl-N - [[6- (aminoiminomethyl) pyridazin-3-yl] methyl] -L-prolinamide;
p) N- (carboxymethyl) -D-cyclohexylalanyl-N - [[1- (aminoiminomethyl) -1,2,3,4-tetrahydropyridin-4-yl] methyl] -L-prolinamide;
c) N- (carboxymethyl) -D-cyclohexylalanyl-N - [[4- (aminoiminomethyl) -2-fluorophenyl] methyl] -L-prolinamide;
r) N- (carboxymethyl) -D-cyclohexylalanyl-N - [[4- (aminoiminomethyl) -2,6-difluorophenyl] methyl] -L-prolinamide;
s) N- (ethylsulfonyl) -D-cyclohexylalanyl-N - [[4- (aminoiminomethyl) phenyl] methyl] -L-prolinamide;
f) N- (carboxymethyl) -D-cyclohexylglycyl-N - [[4- (aminoiminomethyl) phenyl] methyl] -L-prolinamide;
x) N- (carboxymethyl) -D-homophenylalanyl-N - [[4- (aminoiminomethyl) phenyl] methyl] -L-prolinamide;
c) N- (carboxymethyl) -D-homocyclohexylalanyl-N - [[4- (aminoiminomethyl) phenyl] methyl] -L-prolinamide;
h) N- (methylsulfonylacetyl) -L-cyclohexylalanyl-N - [[4- (aminoiminomethyl) phenyl] methyl] -L-prolinamide;
14. The compound or its salt or solvate according to claim 1, characterized in that it is selected from the following compounds:
I) (S-cis) -N - [[4- (aminoiminomethyl) phenyl] methyl] -1- [N- (ethylsulfonyl) -D-phenylalanyl] -1H-indole-2-carboxamide;
II) N- (carboxymethyl) -D-phenylalanyl-N - [[4- (aminoiminomethyl) phenyl] methyl] -L-prolinamide;
III) N- (carboxymethyl) -D-cyclohexylalanyl-N - [[4- (aminoiminomethyl) phenyl] methyl] -L-prolinamide;
Iv) D-cyclohexylalanyl-N - [[4- (aminoiminomethyl) phenyl] methyl] -L-prolinamide;
V) N- (carboxymethyl) -D-cyclohexylalanyl-N - [[5- (aminoiminomethyl) thiophen-2-yl] methyl] -L-prolinamide;
VI) N- (carboxymethyl) -D-cyclohexylalanyl-N - [[1- (aminoiminomethyl) -1, 2, 3, 4-tetrahydropyridin-4-yl] methyl] -L-prolinamide;
VII) N- (carboxymethyl) -D-cyclohexylalanyl-N - [[4- (aminoiminomethyl) -2-fluorophenyl] methyl] -L-prolinamide;
VIII) N- (carboxymethyl) -D-cyclohexylalanyl-N - [[4- (aminoiminomethyl) -2,6-difluorophenyl] methyl] -L-prolinamide.
X-Y-NH-(CH2)r-G
отличающийся тем, что он включает,
а) одновременное или последовательное удаление защитной группы (групп) p из соответствующего соединения формулы II:
(P)X-Y-NH-(CH2)r-G(P)
где (P) Х обозначает радикал Х, который может нести одну или несколько защитных групп Р, независимо выбранных из аминозащитной группы Р для соединения формулы I, где Х включает основную группу NH, и карбоксизащитной группы Р для соединения формулы I, где Х включает карбоксиостаток, и G(P) обозначает радикал G, который может нести одну или несколько независимо выбранных аминозащитных групп Р; или
б) для соединения формулы I, в котором R обозначает
гидрогирование соответствующего соединения формулы I, где R обозначает
в) и далее, когда необходима соль соединения формулы I, образование соли с фармацевтически приемлемой кислотой.18. The method of obtaining the compound according to any one of claims 1 to 9, having the formula I:
XY-NH- (CH 2 ) r -G
characterized in that it includes
a) simultaneous or sequential removal of the protective group (s) p from the corresponding compound of formula II:
(P) XY-NH- (CH 2 ) r -G (P)
where (P) X is a radical X which can carry one or more protecting groups P independently selected from an amino protecting group P for a compound of formula I, where X includes a basic NH group, and a carboxy protecting group P for a compound of formula I, where X includes a carboxy residue , and G (P) denotes the radical G, which can carry one or more independently selected amino protecting groups P; or
b) for a compound of formula I in which R is
hydrogenation of the corresponding compound of formula I, where R is
c) and further, when a salt of a compound of formula I is needed, formation of a salt with a pharmaceutically acceptable acid.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20655394A | 1994-03-04 | 1994-03-04 | |
US08/206,553 | 1994-03-04 | ||
PCT/US1995/002558 WO1995023609A1 (en) | 1994-03-04 | 1995-03-03 | Antithrombotic agents |
Publications (2)
Publication Number | Publication Date |
---|---|
RU96120088A true RU96120088A (en) | 1998-12-27 |
RU2148585C1 RU2148585C1 (en) | 2000-05-10 |
Family
ID=22766894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU96120088A RU2148585C1 (en) | 1994-03-04 | 1995-03-03 | Peptide derivatives, method of their synthesis, pharmaceutical composition and method of thrombin inhibition in mammal |
Country Status (28)
Country | Link |
---|---|
EP (2) | EP0672658B1 (en) |
JP (1) | JP4081138B2 (en) |
KR (1) | KR100337271B1 (en) |
CN (2) | CN1134264C (en) |
AT (1) | ATE250028T1 (en) |
AU (1) | AU684918C (en) |
BR (1) | BR9506979A (en) |
CA (1) | CA2183464A1 (en) |
CZ (1) | CZ294674B6 (en) |
DE (1) | DE69531753T2 (en) |
DK (1) | DK0672658T3 (en) |
ES (1) | ES2206479T3 (en) |
FI (1) | FI963451A (en) |
HU (1) | HU227356B1 (en) |
IL (1) | IL112795A (en) |
MX (1) | MX9603831A (en) |
MY (1) | MY119987A (en) |
NO (1) | NO309034B1 (en) |
NZ (1) | NZ282588A (en) |
PE (1) | PE41696A1 (en) |
PL (1) | PL181306B1 (en) |
PT (1) | PT672658E (en) |
RU (1) | RU2148585C1 (en) |
SI (1) | SI0672658T1 (en) |
TW (1) | TW401403B (en) |
UA (1) | UA67715C2 (en) |
WO (1) | WO1995023609A1 (en) |
ZA (1) | ZA951617B (en) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4421052A1 (en) | 1994-06-17 | 1995-12-21 | Basf Ag | New thrombin inhibitors, their production and use |
DE4443390A1 (en) * | 1994-12-06 | 1996-06-13 | Basf Ag | New dipeptidic p-amidinobenzylamides with N-terminal sulfonyl or aminosulfonyl residues |
JPH10513462A (en) * | 1995-02-10 | 1998-12-22 | ビーエーエスエフ アクチェンゲゼルシャフト | Thrombin inhibitor |
AU708001B2 (en) | 1995-02-17 | 1999-07-29 | Abbott Gmbh & Co. Kg | Novel thrombin inhibitors |
US5629324A (en) * | 1995-04-10 | 1997-05-13 | Merck & Co., Inc. | Thrombin inhibitors |
US5612369A (en) * | 1995-06-07 | 1997-03-18 | 3-Dimensional Pharmaceuticals, Inc. | Thrombin inhibitors |
SA96170106A (en) | 1995-07-06 | 2005-12-03 | أسترا أكتيبولاج | New amino acid derivatives |
FR2739858B1 (en) * | 1995-10-11 | 1997-11-14 | Synthelabo | N-SULFONYL- AND N-SULFAMOYLPEPTIDYLPROLINAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
EP0858262B1 (en) * | 1995-10-24 | 2002-12-04 | Merck & Co., Inc. | Thrombin inhibitors |
TWI238827B (en) | 1995-12-21 | 2005-09-01 | Astrazeneca Ab | Prodrugs of thrombin inhibitors |
NZ331327A (en) * | 1996-02-13 | 2000-01-28 | Akzo Nobel Nv | Serine protease inhibitors having an acylguanidine side chain |
IL120311A (en) * | 1996-03-01 | 2001-10-31 | Akzo Nobel Nv | Serine protease inhibitors and pharmaceutical compositions containing them |
TW442452B (en) * | 1996-03-01 | 2001-06-23 | Akzo Nobel Nv | Serine protease inhibitors having an alkynylamino side chain |
US5811402A (en) * | 1996-03-22 | 1998-09-22 | Eli Lilly And Company | Antithrombotic diamides |
CA2200163A1 (en) * | 1996-03-22 | 1997-09-22 | Michael Robert Wiley | Antithrombotic diamides |
SE9602263D0 (en) | 1996-06-07 | 1996-06-07 | Astra Ab | New amino acid derivatives |
US6200967B1 (en) | 1996-06-25 | 2001-03-13 | Eli Lilly And Company | Anticoagulant agents |
EP1110968B1 (en) * | 1996-06-25 | 2003-10-01 | Eli Lilly & Company | Intermediate for the preparation of Thrombininhibitors as anticoagulant agents |
JP2000514788A (en) * | 1996-06-25 | 2000-11-07 | イーライ・リリー・アンド・カンパニー | Anticoagulant |
SE9602646D0 (en) | 1996-07-04 | 1996-07-04 | Astra Ab | Pharmaceutically useful compounds |
DE19632773A1 (en) * | 1996-08-14 | 1998-02-19 | Basf Ag | New thrombin inhibitors |
DE19632772A1 (en) | 1996-08-14 | 1998-02-19 | Basf Ag | New benzamidines |
IL121474A0 (en) * | 1996-08-23 | 1998-02-08 | Akzo Nobel Nv | Thrombin inhibitors |
TW542822B (en) | 1997-01-17 | 2003-07-21 | Ajinomoto Kk | Benzamidine derivatives |
WO1998051684A1 (en) * | 1997-05-15 | 1998-11-19 | Eli Lilly And Company | Antithrombotic compound |
AR013084A1 (en) | 1997-06-19 | 2000-12-13 | Astrazeneca Ab | USEFUL AMIDINE DERIVATIVES AS THROMBIN INHIBITORS, PHARMACEUTICAL COMPOSITION, USE OF SUCH COMPOUNDS FOR THE PREPARATION OF MEDICINES AND THE PROCESS FOR THE PREPARATION OF THE MENTIONED COMPOUNDS |
DE19734445A1 (en) * | 1997-08-08 | 1999-02-11 | Basf Ag | Lipophilic polymeric UV absorber |
US6740682B2 (en) | 1997-08-29 | 2004-05-25 | Tularik Limited | Meta-benzamidine derivatives as serine protease inhibitors |
EP1009758B1 (en) * | 1997-08-29 | 2005-06-01 | Tularik Limited | Meta-benzamidine derivatives as serine protease inhibitors |
SE9704543D0 (en) | 1997-12-05 | 1997-12-05 | Astra Ab | New compounds |
KR100689923B1 (en) * | 1998-01-26 | 2007-03-09 | 애보트 게엠베하 운트 콤파니 카게 | Thrombin Inhibitors |
AU2424499A (en) * | 1998-01-26 | 1999-08-09 | Basf Aktiengesellschaft | Heterocyclic amidines as callicrein protease inhibitors |
JP2002502852A (en) * | 1998-02-09 | 2002-01-29 | 3−ディメンショナル ファーマシューティカルズ, インコーポレイテッド | Heteroarylamidines, methylamidines and guanidines as protease inhibitors, especially urokinase inhibitors |
US6291514B1 (en) | 1998-02-09 | 2001-09-18 | 3-Dimensional Pharmaceuticals, Inc. | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors |
AU750561B2 (en) | 1998-04-24 | 2002-07-25 | 3-Dimensional Pharmaceuticals, Inc. | Amino acid amidinohydrazones, alkoxyguanidines and aminoguanidines as protease inhibitors |
EP1086946A4 (en) * | 1998-06-08 | 2003-03-05 | Ajinomoto Kk | Benzamidine derivative |
SE9804313D0 (en) | 1998-12-14 | 1998-12-14 | Astra Ab | New compounds |
EP1058549A4 (en) * | 1998-12-23 | 2003-11-12 | Bristol Myers Squibb Pharma Co | THROMBIN OR FACTOR Xa INHIBITORS |
KR20000047461A (en) * | 1998-12-29 | 2000-07-25 | 성재갑 | Thrombin inhibitors |
CA2355792A1 (en) | 1999-01-13 | 2000-07-20 | Astrazeneca Ab | New amidinobenzylamine derivatives and their use as thrombin inhibitors |
CA2362390A1 (en) * | 1999-02-09 | 2000-08-17 | 3-Dimensional Pharmaceuticals, Inc. | Heteroaryl amidines, methylamidines and guanidines as protease inhibitors |
PL352824A1 (en) * | 1999-04-09 | 2003-09-08 | Abbott Gmbh & Co.Kg | Prodrugs of thrombin inhibitors |
AR023510A1 (en) | 1999-04-21 | 2002-09-04 | Astrazeneca Ab | A TEAM OF PARTS, PHARMACEUTICAL FORMULATION AND USE OF A THROMBIN INHIBITOR. |
FR2793248B1 (en) * | 1999-05-03 | 2001-06-29 | Adir | NOVEL 2,3-METHANO-AMINOACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
AU748949B2 (en) * | 1999-06-23 | 2002-06-13 | Merck & Co., Inc. | Integrin receptor antagonists |
RU2222529C2 (en) * | 1999-10-28 | 2004-01-27 | Санкио Компани, Лимитед | Derivatives of benzamidine |
CN1172905C (en) | 1999-12-14 | 2004-10-27 | 昭和电工株式会社 | Process for producing of cyanobenzyamine of derivative |
SE0000382D0 (en) | 2000-02-07 | 2000-02-07 | Astrazeneca Ab | New process |
SE0001803D0 (en) | 2000-05-16 | 2000-05-16 | Astrazeneca Ab | New compounds i |
US7129233B2 (en) | 2000-12-01 | 2006-10-31 | Astrazeneca Ab | Mandelic acid derivatives and their use as thrombin inhibitors |
AR035216A1 (en) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | MANDELIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE DERIVATIVES, USE OF THESE DERIVATIVES FOR THE MANUFACTURE OF MEDICINES, TREATMENT METHODS, PROCESSES FOR THE PREPARATION OF THESE DERIVATIVES, AND INTERMEDIARY COMPOUNDS |
AU2002230836A1 (en) | 2000-12-18 | 2002-07-01 | Merck & Co., Inc. | Benzylamine derivatives and their use as thrombin inhibitors |
US6528503B2 (en) | 2000-12-18 | 2003-03-04 | Merck & Co., Inc. | Thrombin inhibitors |
WO2002064559A2 (en) | 2001-02-09 | 2002-08-22 | Merck & Co., Inc. | Thrombin inhibitors |
AR034517A1 (en) | 2001-06-21 | 2004-02-25 | Astrazeneca Ab | PHARMACEUTICAL FORMULATION |
DE50310038D1 (en) | 2002-03-11 | 2008-08-07 | Curacyte Ag | INGREDIENTS OF UROKINASE, THEIR PREPARATION AND USE |
AU2003210055A1 (en) * | 2002-03-22 | 2003-10-08 | Lg Life Sciences Ltd. | New crystalline forms of (2S)-N-5-[amino(imino)methyl]-2-thienylmethyl-1-(2R)-2-[(carboxymethyl)amino]-3,3-diphenylpropanoyl-2-pyrrolidinecarboxamide nH20 |
PL372596A1 (en) * | 2002-03-22 | 2005-07-25 | Lg Life Sciences Ltd. | Maleic acid salt of (2s)-n-{5-[amino(imino)methyl]-2-thienyl}methyl-1-{(2r)-2-[(carboxymethyl)amino]3,3-diphenylpropanoyl}-2-pyrrolidine carboxamide and a process for |
US7084134B2 (en) | 2002-05-02 | 2006-08-01 | Merk & Co., Inc. | Thrombin inhibitors |
SE0201659D0 (en) | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Modified release pharmaceutical formulation |
SE0201661D0 (en) | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | New salts |
DE10301300B4 (en) | 2003-01-15 | 2009-07-16 | Curacyte Chemistry Gmbh | Use of acylated 4-amidino- and 4-guanidinobenzylamines for the inhibition of plasma kallikrein |
KR20050118708A (en) | 2003-04-03 | 2005-12-19 | 메르크 파텐트 게엠베하 | Pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl)-phenylamide) derivatives and related compounds for use as inhibitors of coagulation factor xa in the treatment of thrombo-embolic diseases |
US7781424B2 (en) | 2003-05-27 | 2010-08-24 | Astrazeneca Ab | Modified release pharmaceutical formulation |
DE10342108A1 (en) * | 2003-09-11 | 2005-04-14 | Curacyte Chemistry Gmbh | Basic substituted benzylamine analogs as coagulation factor Xa inhibitors, their preparation and use |
FR2867780B1 (en) * | 2004-03-19 | 2006-05-19 | Servier Lab | NOVEL 4-OXO-4,6,7,8-TETRAHYDROPYRROLO (1,2-A) PYRAZINE-6-CARBOXAMIDE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
US7795205B2 (en) | 2004-04-12 | 2010-09-14 | Canyon Pharmaceuticals, Inc. | Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor |
TWI396686B (en) * | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | Cyclic amide derivative, and its production and use |
US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
AU2006259525B2 (en) | 2005-06-14 | 2012-05-24 | Gpcr Therapeutics, Inc | Pyrimidine compounds |
DE102005044319A1 (en) | 2005-09-16 | 2007-03-22 | Curacyte Chemistry Gmbh | 2- (Aminomethyl) -5-chloro-benzylamide derivatives and their use as inhibitors of coagulation factor Xa |
KR101276847B1 (en) | 2006-01-12 | 2013-06-18 | 엘지전자 주식회사 | Processing multiview video |
WO2007081176A1 (en) | 2006-01-12 | 2007-07-19 | Lg Electronics Inc. | Processing multiview video |
US7951823B2 (en) | 2006-05-23 | 2011-05-31 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
DE102006050672A1 (en) | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | New glycylglycine derivatives with a benzylsulfonylamido group and an amidino-organylamido group at the opposite chain ends, used in drugs for reducing loss of blood, e.g. in operations |
TW200827336A (en) | 2006-12-06 | 2008-07-01 | Astrazeneca Ab | New crystalline forms |
ATE493174T1 (en) * | 2007-01-10 | 2011-01-15 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS CHANNEL-ACTIVATE PROTEASE INHIBITORS |
PT2268635E (en) | 2008-04-21 | 2015-10-06 | Taigen Biotechnology Co Ltd | Heterocyclic compounds |
CN102924567B (en) * | 2008-10-28 | 2014-06-04 | 上海医药工业研究院 | Peptide compound and preparation method and use of peptide compound |
CN101724016B (en) * | 2008-10-28 | 2013-09-25 | 上海医药工业研究院 | Peptide compound and preparation method and application thereof |
WO2010056847A2 (en) | 2008-11-13 | 2010-05-20 | Taigen Biotechnology Co., Ltd. | Lyophilization formulation |
CN102464701B (en) | 2010-11-08 | 2015-10-21 | 上海医药工业研究院 | One class novel cpd, Preparation Method And The Use |
ES2654440T3 (en) * | 2010-12-21 | 2018-02-13 | The Medicines Company (Leipzig) Gmbh | Trypsin-like serine protease inhibitors, their preparation and use as selective inhibitors of coagulation factors IIa and Xa |
GB2494851A (en) * | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
GB201212081D0 (en) * | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
GB2510407A (en) * | 2013-02-04 | 2014-08-06 | Kalvista Pharmaceuticals Ltd | Aqueous suspensions of kallikrein inhibitors for parenteral administration |
CN105218561B (en) * | 2014-06-25 | 2018-10-30 | 上海艾力斯医药科技有限公司 | Annelated pyrimidines ring derivatives, preparation method and application |
GB201805174D0 (en) * | 2018-03-29 | 2018-05-16 | Univ Leeds Innovations Ltd | Compounds |
CN109224139B (en) * | 2018-05-09 | 2020-08-18 | 祖晓麟 | Thermosensitive heart stent |
IL311042A (en) * | 2018-05-29 | 2024-04-01 | Omeros Corp | Masp-2 inhibitors and methods of use |
WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
KR20220110530A (en) | 2019-12-04 | 2022-08-08 | 오메로스 코포레이션 | MASP-2 Inhibitors and Methods of Use |
AU2020397894A1 (en) | 2019-12-04 | 2022-06-30 | Omeros Corporation | MASP-2 inhibitors and methods of use |
GB202107722D0 (en) | 2021-05-28 | 2021-07-14 | Lunac Therapeutics Ltd | Factor XIIA Inhibitors |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU178398B (en) * | 1979-06-12 | 1982-04-28 | Gyogyszerkutato Intezet | Process for producing new agmatine derivatives of activity against haemagglutination |
IL99527A (en) * | 1990-09-28 | 1997-08-14 | Lilly Co Eli | Tripeptide antithrombotic agents |
SE9102462D0 (en) * | 1991-08-28 | 1991-08-28 | Astra Ab | NEW ISOSTERIC PEPTIDES |
ZA928581B (en) * | 1991-11-12 | 1994-05-06 | Lilly Co Eli | Antithrombotic agents |
SE9103612D0 (en) * | 1991-12-04 | 1991-12-04 | Astra Ab | NEW PEPTIDE DERIVATIVES |
AU675981B2 (en) * | 1992-12-02 | 1997-02-27 | Bristol-Myers Squibb Company | Guanidinyl-substituted heterocyclic thrombin inhibitors |
SE9301916D0 (en) | 1993-06-03 | 1993-06-03 | Ab Astra | NEW PEPTIDES DERIVATIVES |
CA2140598C (en) | 1994-01-27 | 2010-03-09 | Masahiro Ohshima | Prolineamide derivatives |
-
1995
- 1995-02-27 IL IL11279595A patent/IL112795A/en not_active IP Right Cessation
- 1995-02-27 ZA ZA9501617A patent/ZA951617B/en unknown
- 1995-03-02 MY MYPI95000543A patent/MY119987A/en unknown
- 1995-03-03 PL PL95320637A patent/PL181306B1/en not_active IP Right Cessation
- 1995-03-03 BR BR9506979A patent/BR9506979A/en not_active Application Discontinuation
- 1995-03-03 ES ES95301374T patent/ES2206479T3/en not_active Expired - Lifetime
- 1995-03-03 CN CNB951928996A patent/CN1134264C/en not_active Expired - Fee Related
- 1995-03-03 CZ CZ19962584A patent/CZ294674B6/en not_active IP Right Cessation
- 1995-03-03 SI SI9530692T patent/SI0672658T1/en unknown
- 1995-03-03 KR KR1019960704860A patent/KR100337271B1/en not_active IP Right Cessation
- 1995-03-03 UA UA96093453A patent/UA67715C2/en unknown
- 1995-03-03 MX MX9603831A patent/MX9603831A/en unknown
- 1995-03-03 DE DE69531753T patent/DE69531753T2/en not_active Expired - Lifetime
- 1995-03-03 AU AU19752/95A patent/AU684918C/en not_active Ceased
- 1995-03-03 JP JP52300795A patent/JP4081138B2/en not_active Expired - Fee Related
- 1995-03-03 CN CNB031367569A patent/CN100491348C/en not_active Expired - Fee Related
- 1995-03-03 PT PT95301374T patent/PT672658E/en unknown
- 1995-03-03 HU HU9602408A patent/HU227356B1/en not_active IP Right Cessation
- 1995-03-03 DK DK95301374T patent/DK0672658T3/en active
- 1995-03-03 NZ NZ282588A patent/NZ282588A/en not_active IP Right Cessation
- 1995-03-03 EP EP95301374A patent/EP0672658B1/en not_active Expired - Lifetime
- 1995-03-03 PE PE1995263336A patent/PE41696A1/en not_active Application Discontinuation
- 1995-03-03 CA CA002183464A patent/CA2183464A1/en not_active Abandoned
- 1995-03-03 RU RU96120088A patent/RU2148585C1/en not_active IP Right Cessation
- 1995-03-03 WO PCT/US1995/002558 patent/WO1995023609A1/en active IP Right Grant
- 1995-03-03 EP EP03011805A patent/EP1361212A1/en not_active Withdrawn
- 1995-03-03 AT AT95301374T patent/ATE250028T1/en active
- 1995-03-04 TW TW084102067A patent/TW401403B/en active
-
1996
- 1996-09-03 NO NO963684A patent/NO309034B1/en not_active IP Right Cessation
- 1996-09-03 FI FI963451A patent/FI963451A/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU96120088A (en) | ANTITROMBOTIC AGENTS | |
EP0073143B1 (en) | Novel complex amido and imido derivatives of carboxyalkyl peptides and thioethers and ethers of peptides | |
US6420427B1 (en) | Aminobutyric acid derivatives | |
FI95693B (en) | Process for the preparation of therapeutically useful amino acid derivatives | |
CA3183740A1 (en) | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections | |
ES2214021T3 (en) | FUNCTIONALIZED DERIVATIVES OF GLICINAMIDS WITH SIDE CHAIN FOR RENT AND ALKYLENE AS INHIBITORS OF FARNESIL-TRANSFERASA. | |
KR100462974B1 (en) | Thrombin Inhibitors | |
AU3482099A (en) | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | |
CA2153069A1 (en) | Cyclic sulfone moiety-containing hydroxyethylamine retroviral protease inhibitors | |
CA2146059A1 (en) | Imidazole-containing inhibitors of farnesyl protein transferase | |
WO1997049679A1 (en) | Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient | |
US4766110A (en) | Novel complex amido and imido derivatives of carboxyalkyl peptides | |
KR20140145203A (en) | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators | |
EP0932606B1 (en) | Inhibitors of prenyl transferases | |
ES2308181T3 (en) | PROTEASA INHIBITORS. | |
RU2212404C2 (en) | Derivatives of indole and pharmaceutical composition comprising thereof | |
JPH0820597A (en) | Heterocyclic carbonyl compound having thrombin-inhibiting action | |
CZ159197A3 (en) | Metalloprotease inhibitors, process of their preparation and pharmaceutical composition containing thereof | |
ES2237917T3 (en) | CERTAIN TIOLIC INHIBITORS SUBSTITUTED WITH HETEROARILO CONVERSORA OF ENDOTELINA. | |
JP2008512476A (en) | Acyclic 1,3-diamine and use thereof | |
CA2400862A1 (en) | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | |
CA2333947A1 (en) | Pyrazolopyridine compounds as adenosine a1 antagonist for male sterility | |
PT100865A (en) | A PEPTIDE ISOSTERES CONTAINING A HETEROCYLIC, PREPARATION PROCESS FOR THEIR INTERMEDIARIES, USE AND PHARMACEUTICAL COMPOSITIONS | |
US5043346A (en) | Amino acid esters, pharmaceuticals containing them, and the use thereof in learning disorders | |
PT101026A (en) | 6-PHENYL-5-AMINO-4-HYDROXY-HEXANOYL-VALYL-GUANIDINES SUBSTITUTED AS HIV PROTEASE INHIBITORS |